moxalactam

moxalactam

 [mok´sah-lak″tam]
a third generation cephalosporinantibiotic having a broad spectrum of activity, effective against β-lactamase–producing strains of Haemophilus influenzae and gram-negative enteric bacilli, including multiple drug-resistant strains.

mox·a·lac·tam

(moks'a-lak'tam),
A third-generation cephalosporin with a broad spectrum of antibacterial action; causes bleeding disorders, which limit its use.

mox·a·lac·tam

(MOX) (moks'ă-lak'tam)
A third-generation cephalosporin with a broad spectrum of antibacterial action; causes bleeding disorders, which limit its use.

mox·a·lac·tam

(moks'ă-lak'tam)
Third-generation cephalosporin with a broad spectrum of antibacterial action.
References in periodicals archive ?
Sensitive and specific phenotypic assay for metallo-beta-lactamase detection in Enterobacteria by use of moxalactam disk supplemented with EDTA.
Se ha demostrado que las cefamicinas (cefoxitina y moxalactam) son potentes inductores de la expresion del gen mecA, directamente relacionado con la mayor sintesis de la proteina PBP2a in vitro (Acosta et al., 2012; Aleixandre et al., 2014).
Brucella canis infection in a 17-monthold child successfully treated with moxalactam. J Pediatr.
and Nalidixic acid Cefotetan 2 Gram-positive strains 10 Acriflavine 5 Listeria monocytogenes Fosfomycin 10 400 (CH) Moxalactam 15 Listeria spp.
Carbapenems were the most potent agents against the Enterobacteriaceae isolates, followed by moxalactam, tigecycline, and amikacin.
Evaluation of three techniques for detection of low-level methicillin-resistant staphylococcus aureus (mrsa): A disk diffusion method with cefoxitin and moxalactam, the vitek 2 system, and the mrsa-screen latex agglutination test.
Susceptibility to the following antibiotics penicillin G, cefoxitin, moxalactam, kanamycin, amikacin, tobramycin, gentamicin, erythromycin, lincomycin, tetracycline, pristinamycin, furans, ofloxacin, trimethoprim-sulfamethoxazole, rifampicin, fusidic acid, fosfomycin, mupirocin, high mupirocin, vancomycin, teicoplanin, and linezolid was determined according to the recommendations of the Committee for Antimicrobial Testing of the French Society of Microbiology (CASFM) (http://www.sfm-microbiologie.org/) 10].
Because fluoroquinolones are one of the most commonly used antibiotics associated with a greater risk for CDI in humans, we did not use moxalactam and norfloxacin (a fluoroquinolone) supplementation as has been previously done in other culture studies because its use seems to introduce selection bias towards fluoroquinolone-resistant isolates as early noticed [5, 6,14].
Other [beta]-lactam antibiotics have also been employed, e.g., sulbenicillin (Zhang et al., 2000), augmentin (Ieamkhang and Chatchawankanphanich, 2005), meropenem and moxalactam (Ogawa and Mii, 2007).